Erratum to: New oral anticoagulants in atrial fibrillation: a reappraisal of trial results looking at absolute figures

Erratum to: Intern Emerg Med (2013) 8:115–122 DOI 10.1007/s11739-012-0886-6

The original publication of this article unfortunately contained an error in Table 3. Data of mortality and major bleeding in the last column related to apixaban should be corrected as follow:

	Dabigatran 110	Dabigatran 150	Rivaroxaban	Apixaban
All strokes + SE
∆ versus warfarin	1.6	5.8	3.0	3.3
NNT	625	172	333	300
Ischemic/unknown stroke
∆ versus warfarin	−1.4	2.8	1.2	0.8
NNT	a	357	833	1250
Mortality (all cause)
∆ versus warfarin	3.8	4.9	4.1	4.2
NNT	263	204	244	238
Major bleeding
∆ versus warfarin	6.5	2.5	−2.0	9.6
NNT	154	400	a	104
Intracranial bleeding
∆ versus warfarin	5.1	4.4	2.0	4.7
NNT	196	227	500	213

1. Positive figures express advantage in events spared vs warfarin
2. ∆ Absolute differences, NNT number needed to treat to avoid one event in 1000 patients per year, SE systemic embolism
3. ^aNNT inappropriate